Last updated on December 2018

Study of IMCY-0098 in Patients With Recent Onset Type 1 Diabetes


Brief description of study

This clinical study will evaluate the safety of an innovative approach expected to be disease-modifying by stopping the auto-immune-mediated destruction of islet -cells in the pancreas. Three doses of the investigational product will be tested in successive cohorts. Although safety is the first objective of this study, we will gather efficacy data and perform a set of immunological tests to further understand the mechanism of action of this new approach in young adults with recent onset type 1 diabetes.

Clinical Study Identifier: NCT03272269

Contact Investigators or Research Sites near you

Start Over

Pierre Vandepapelière, MD

Bispebjerg and Frederiksberg Hospital
Copenhagen, Denmark

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.